ARTICLE | Company News
Genaera, MedImmune Inc. deal
August 23, 2004 7:00 AM UTC
Under a 2001 deal, GENR received a $500,000 milestone payment from MEDI triggered by the start of a Phase I trial of the partners' neutralizing interleukin-9 (IL-9) antibody for asthma (see BioCentur...